Form 4: Akari Therapeutics Interim CFO Wendy F. DiCicco Acquires Shares Through Restricted Stock Units

Wendy F. DiCicco, Interim CFO of Akari Therapeutics Plc, reports acquisition of 158,473,915 ordinary shares through restricted stock units.

Summary

• On May 1, 2024, Wendy F. DiCicco, the Interim CFO of Akari Therapeutics Plc, acquired 158,473,915 ordinary shares.
• These shares were granted as restricted stock units (RSUs) under the Issuer's 2023 Equity Incentive Plan.
• Each RSU represents the right to receive one ordinary share with a par value of $0.0001.
• The RSUs will vest on May 1, 2025, contingent upon DiCicco's continued service with Akari Therapeutics.
• In the event of termination without cause, the RSUs will continue to vest or be accelerated at the Issuer's discretion.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing indicating insider ownership. It's neutral to slightly positive as it shows the CFO's commitment to the company.

Positives

• The grant of RSUs to the Interim CFO aligns her interests with those of the shareholders.
• The vesting schedule incentivizes continued service with the company.

Risks

• The value of the RSUs is dependent on the future performance of Akari Therapeutics' ordinary shares.
• If Wendy F. DiCicco leaves the company for cause before the vesting date, the RSUs will be forfeited.

Future Outlook

The RSUs will vest on May 1, 2025, subject to the Reporting Person's continued service with the Issuer on the vesting date.

Industry Context

This type of equity compensation is common in the biotechnology industry to attract and retain key personnel.

Comparison to Industry Standards

• Granting restricted stock units (RSUs) to executives is a standard practice in the biotech industry.
• Companies like Amgen, Biogen, and Gilead Sciences use similar equity incentive plans to align management's interests with shareholders.
• The vesting period of one year is relatively short compared to some companies that use multi-year vesting schedules.

Stakeholder Impact

• The acquisition of shares by the Interim CFO could be viewed positively by shareholders, as it demonstrates confidence in the company's future.
• Employees may also view this positively, as it aligns management's interests with the company's success.

Key Dates